Rats that differentially respond to cocaine differ in their dopaminergic storage capacity of the nucleus accumbens

Michel M. M. Verheij,* Eric L. W. de Mulder,* Elvira De Leonibus,†‡ Karen M. J. van Loo§ and Alexander R. Cools*

*Department of Cognitive Neuroscience, Division of Psychoneuropharmacology, Radboud University of Nijmegen, Nijmegen, The Netherlands
†Department of Genetics and Molecular Biology, La Sapienza University of Rome, Rome, Italy
‡Telethon Institute of Genetics and Medicine, Naples, Italy
§Department of Molecular Animal Physiology, Nijmegen Center for Molecular Life Sciences, Radboud University of Nijmegen, Nijmegen, The Netherlands

Abstract
Cocaine (COC) inhibits the re-uptake of dopamine. However, the dopamine response to COC also depends on dopamine inside storage vesicles. The aim of this study was to investigate whether rats that differentially respond to COC differ in their dopaminergic storage capacity of the nucleus accumbens. Total and vesicular levels of accumbal dopamine as well as accumbal vesicular monoamine transporter-2 levels were established in high (HR) and low responders (LR) to novelty rats. Moreover, the effects of reserpine (RES) on the COC-induced increase of extracellular accumbal dopamine were investigated. HR displayed higher accumbal levels of total and vesicular dopamine than LR. Moreover, HR displayed more accumbal vesicular monoamine transporters-2 than LR. COC increased extracellular accumbal dopamine more strongly in HR than in LR. A low dose of RES prevented the COC-induced increase of accumbal dopamine in LR, but not in HR. A higher dose of RES was required to inhibit the COC-induced increase of accumbal dopamine in HR. These data demonstrate that HR were marked by a larger accumbal dopaminergic storage pool than LR. It is hypothesized that HR are more sensitive to COC than LR, because COC can release more dopamine from accumbal storage vesicles in HR than in LR.

Keywords: cocaine pharmacology, dopamine pools, individual differences, plasmalemmal transporters, reserpine pharmacology, vesicular transporters.

J. Neurochem. (2008) 105, 2122–2133.

Individual differences in the susceptibility to psychostimulants have extensively been reported, both in humans (Jaffe and Archer 1987; Ball et al. 1994; Gynther et al. 1995; van den Bree et al. 1998) and in animals (Piazza et al. 1989, 2000; Mantsch et al. 2001). This study focused on two types of rat that differ in their acute response to cocaine (COC). These individuals are selected on the basis of their locomotor response to a novel open-field and, accordingly, labeled high (HR) and low responders (LR) to novelty (Piazza et al. 1989, 1991b; Rouge-Pont et al. 1993; Delfu et al. 1996; Bevins et al. 1997; Cools and Gingras 1998; Cools and Tuinstra 2003; Kabbaj 2004). Previous studies have demonstrated that COC increases the locomotor response and the extracellular levels of accumbal dopamine more strongly in HR than in LR (Hooks et al. 1991b; Chefer et al. 2003).

Cocaine inhibits the re-uptake of monoamines by blocking plasmalemmal monoamine transporters (Lee et al. 2001). Several studies have suggested that individual differences in the re-uptake of dopamine may explain individual differences in the response to COC (Sabeti et al. 2002, 2003; Chefer et al. 2003; Briegleb et al. 2004; Zahniser and Sorkin 2004).

Received October 15, 2007; revised manuscript received February 6, 2008; accepted February 7, 2008.

Address correspondence and reprint requests to M. M. M. Verheij, Department of Cognitive Neuroscience (CNS), Division of Psychoneuropharmacology (PNF), PO Box 9101, Faculty of Medicine, Radboud University (RU) of Nijmegen, Nijmegen 6500 HB, The Netherlands. E-mail: M.Verheij@cns.umcn.nl

1Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

Abbreviations used: ADHD, attention deficit hyperactivity disorder; COC, cocaine; DAT, dopamine transporter; HR, high responders to novelty; LR, low responders to novelty; RES, reserpine; VMAT-2, vesicular monoamine transporters-2.
However, behavioral and neurochemical studies have demonstrated that the response to COC depends on storage vesicles as well (Scheel-Kruger et al. 1977; McMillen et al. 1980; McMillen 1983; Davis 1985; Hurd and Ungerstedt 1989; Sulzer and Rayport 1990; Florin et al. 1995; Pifl et al. 1995; Venton et al. 2006). It is unknown to what extent individual differences in the dopaminergic storage capacity contribute to individual differences in response to COC. The above-mentioned finding that HR are marked by a larger COC-induced increase of accumbal dopamine than LR suggests that HR store more accumbal dopamine inside storage vesicles than LR. Accordingly, total and vesicular levels of accumbal dopamine were measured in both types of rat. Given that vesicular monoamine transporters-2 (VMAT-2) control the amount of dopamine inside storage vesicles (Pothos et al. 2000; Pothos 2002), the levels of the accumbal VMAT-2 were also measured. Based on the notion that LR store less accumbal dopamine inside vesicles than HR, it was hypothesized that the nucleus accumbens of LR contains less VMAT than the nucleus accumbens of HR.

The drug reserpine (RES) inhibits the VMAT-mediated uptake of cytoplasmatic monoamines into storage vesicles (Kirshner et al. 1963; Henry et al. 1998). As the extracellular levels of monoamines strongly depend on an intact shuttle between cytoplasmatic and vesicular monoamines (Schoemaker and Nicolson 1983; Leviel et al. 1989; Arbuthnott et al. 1990), RES decreases the extracellular levels of accumbal dopamine (Verheij and Cools 2007). The present study also investigated the effects of RES on the COC-induced increase of extracellular accumbal dopamine. It was hypothesized that COC-treated LR, which are supposed to be marked by a relatively small storage pool containing low amounts of VMAT, are more vulnerable to the RES-induced dopamine depletion than COC-treated HR, which are supposed to be marked by a relatively large storage pool containing high amounts of VMAT.

**Experimental procedures**

See Appendix S1 for the full version of this section.

**Open-field selection**

The open-field selection is described by Cools et al. (1990). Rats that habituated in less than 480 s and walked less than 4800 cm in 30 min were labeled LR. Rats that habituated after 840 s and walked more than 6000 cm in 30 min were labeled HR; 48 adult male LR and 59 adult male HR that were selected from the outbred strain of Nijmegen Wistar rats were used throughout this study.

**Vesicular levels of accumbal dopamine (experiment 1)**

The aim of this experiment was to measure the levels of vesicular dopamine in punches of the nucleus accumbens. Seven days after the open-field selection, 10 LR and 10 HR were killed by decapitation. Their brains were quickly removed, immediately placed into a brain matrix, and subsequently sectioned at 3.0 mm intervals (Mong et al. 2003). Coronal incisions were made at anterior/posterior 9.0 and 12.0 mm (Paxinos and Watson 1986). The most caudal incision was made at the position where the two optic nerves fuse with the optic chiasm (Fig. 1). From the identified slice, one punch of accumbal tissue was obtained from either side of the brain using a 1.22 mm i.d. stainless steel needle (Szczypka et al. 2001). The anterior commissure was used as a landmark to reliable punch out accumbal tissue (Fig. 1). For each rat, tissue of the left and right punch was pooled (total volume $2 \times 3.5 \text{ mm}^3 = 7.0 \text{ mm}^3$). The remaining tissue was fixated in $p$-formaldehyde solution in order to allow histological verification of the exact position of the punch needle. Purified accumbal vesicles were prepared by ultracentrifugation (Staal et al. 2000). Vesicular dopamine levels were obtained according to the procedures described by Sandoval et al. (2003). The final supernatant was injected into a high performance liquid chromatography–electrochemical detection system for separation and quantification of vesicular dopamine. Vesicular dopamine levels were normalized for variation in protein loading using the total protein concentration of the first supernatant (Sandoval et al. 2003).
Accumbal VMAT-2 levels and total levels of accumbal dopamine (experiment 2)

To investigate whether the putative individual differences in accumbal dopaminergic storage capacity were associated with individual differences in VMAT-2 levels, accumbal punches of 12 LR and 12 HR (isolated as described above) were analyzed for VMAT-2 expression. The punches were homogenized in phosphate-buffered saline containing urea, sodium dodecyl sulfate, β-mercaptoethanol, phenylmethylsulfonyl fluoride, and soybean trypsin inhibitor (Jensen et al. 1998). Next, proteins were separated on an 8% sodium dodecyl sulfate–polyacrylamide gel and transferred to nitrocellulose membranes. VMAT-2 expression was examined using the anti-VMAT-2 antibody (1:1000, AB1767; Chemicon, Hampshire, UK) and anti-β-tubulin antibody (1:3000, E7; Chu and Klipykowski 1989). Band intensities were corrected for background.

For quantification of the total levels of accumbal dopamine, the samples that were used to assess the amount of VMAT were diluted and immediately injected into the high performance liquid chromatography–electrochemical detection system. VMAT and total dopamine levels were normalized for variation in protein loading using the levels of tubulin (Hedtjarn et al. 2002).

Effects of reserpine on the cocaine-induced increase of extracellular accumbal dopamine (experiment 3)

The aim of this experiment was to investigate the effects of RES on the COC-induced increase of extracellular accumbal dopamine. A group of 26 LR and 37 HR were unilaterally implanted with a guide cannula directed at the right nucleus accumbens according to previously described procedures (Verheij and Cools 2007). The rats were allowed to recover from surgery for the next 7–10 days in dialysis cages. At the first day of the experiment, a dialysis probe was inserted into the guide cannula. Four hours following probe insertion, HR and LR were injected with RES or its solvent (see below). At the second day of the experiment, accumbal dialysates were analyzed for dopamine according to previously described procedures (De Leonibus et al. 2006). As soon as the dopamine samples differed less than 10%, three baseline samples were taken. The average of these three samples served as control value (100%) to study the drug-induced changes of accumbal dopamine. Immediately after the third baseline sample was taken, rats that were treated with RES or its solvent on day 1 were injected with COC or saline (see below). These rats were subsequently exposed to a cage that was slightly larger than their home cage and lacked sawdust on the floor (Verheij and Cools 2007). After this exposure to novelty, the accumbal extracellular concentration of dopamine was recorded (at 5 min intervals) for a period of 90 min.

Both LR and HR were injected with 1 mg/kg of RES on day 1 and 15 mg/kg of COC on day 2. Because 1 mg/kg of RES had no effect on the COC-induced increase of extracellular dopamine in HR, a new group of HR was pre-treated with 2 mg/kg of RES on day 1. All drugs were given i.p. in a volume of 1 mL/kg. At the end of the microdialysis experiments, rats were given an overdose of pentobarbital and were intracardially perfused with p-formaldehyde. Vibratome sections were cut to verify the location of the microdialysis probe.

Analysis of the data (experiments 1–3)

Data were statistically analyzed using an ANOVA with the factor type of rat (experiments 1 and 2) or the factors type of rat, treatment, and time (experiment 3). In case HR and LR were differentially sensitive to COC, the effects of RES on the effects of COC were statistically analyzed per type of rat. The relationship between the mean COC-induced increase of accumbal extracellular dopamine and the response to novelty on the open-field (traveled distance and habituation time) were evaluated by mean of Pearson’s two-tailed correlation analysis. All data were expressed as mean ± SEM. A probability level of p < 0.05 was taken as significant in every test.

Results

Open-field selection

The open-field selection procedure revealed 24% LR and 30% HR. The average distance traveled in 30 min was 3493 ± 191 and 8643 ± 373 cm in LR and HR, respectively. The average habituation time was 324 ± 28 s in LR and 1340 ± 66 s in HR. Rats that did not fulfill the criteria (46%) were not included in this study.

Vesicular levels of accumbal dopamine (experiment 1)

Histological verification revealed that three LR and three HR had to be excluded because incorrect placement of the punch needle. Figure 1 shows the coronal region of the nucleus accumbens in which all correctly placed punches were located.

The vesicular levels of accumbal dopamine are depicted in Fig. 2 (LR: n = 9 and HR: n = 9). The nucleus accumbens of LR was marked by smaller levels of dopamine inside storage vesicles than the nucleus accumbens of HR [Fig. 2a; one-way ANOVA: type effect: n.s.], demonstrating that similar pieces of tissue were punched from the nucleus accumbens of both types of rat.

Accumbal VMAT-2 levels and total levels of accumbal dopamine (experiment 2)

The accumbal VMAT-2 immunoreactivity levels are depicted in Fig. 3 (LR: n = 10 and HR: n = 10). The anti-VMAT-2 antibody labeled both a relatively small protein of ~70 kDa and a relatively large protein of ~110 kDa (Fig. 3a; Yao et al. 2004; Yao and Hersh 2007). A one-way ANOVA revealed that the levels of both the small and the large VMAT-2 protein were significant less in the nucleus accumbens of LR than of HR [Fig. 3b; (VMAT-2 ~70 kDa): type-effect: F(1,16) = 6.490, p = 0.020; Fig. 3c (VMAT-2 ~110 kDa): type effect: F(1,18) = 6.822, p = 0.018]. The antibody raised against the loading control tubulin selectively labeled a protein of ~50 kDa (Fig. 3a; Kong et al. 1999). The accumbal tubulin levels were equal in LR and HR (Fig. 3d; one-way ANOVA: type effect: n.s.), demonstrating that similar pieces of tissue were punched
from the nucleus accumbens of both types of rat (Hedtjarn et al. 2002). The total levels of accumbal dopamine are depicted in Fig. 4 (LR: n = 10 and HR: n = 10). The total levels of dopamine were significant less in the nucleus accumbens of LR than in the nucleus accumbens of HR [Fig. 4; one-way ANOVA: type-effect: $F_{(1,18)} = 6.000, p = 0.023$].

Effects of reserpine on the cocaine-induced increase of extracellular accumbal dopamine (experiment 3)

The dialysis probes of the present study were located in the same region of the nucleus accumbens as the dialysis probes of a previous study (see Fig. 2 of Verheij and Cools 2007). Histological verification revealed that two HR and two LR had to be excluded because of incorrect placement of the dialysis probe. One additional HR had to be excluded from analysis because of obstruction of the microdialysis probe.

The baseline absolute concentration of extracellular accumbal dopamine was 0.68 ± 0.11 pg/10 μL in LR (mean ± SEM of rats belonging to the pooled groups of solvent-treated LR: n = 8 + 8 = 16) and 0.84 ± 0.15 pg/10 μL in HR (mean ± SEM of rats belonging to the pooled groups of solvent-treated HR: n = 9 + 8 = 17). Extracellular dopamine levels after RES were 0.58 ± 0.07 pg/10 μL in LR (1 mg/kg: n = 8) and 0.31 ± 0.05 pg/10 μL in HR (1 and 2 mg/kg pooled: n = 8 + 9 = 17). The RES-induced decrease of the basal levels of dopamine in LR [100% – (0.58/0.68 pg) = 15%] and HR [100% – (0.31/0.84 pg) = 63%] are very similar to the previously reported RES-induced decrease of the basal levels of dopamine in these rats (Verheij and Cools 2007). No rat had to be excluded because of undetectable dopamine levels.

The effects of saline (=solvent of COC) on the extracellular amount of accumbal dopamine in novelty-challenged LR and HR are depicted in Fig. 5 (LR saline: n = 8 and HR saline: n = 9). The accumbal dopamine response to novelty was larger in saline-treated HR than in saline-treated LR [Fig. 5; two-way ANOVA: type × time effect: n.s; type effect: $F_{(1,15)} = 12.733, p = 0.003$]. One sample t-test revealed that the extracellular levels of dopamine significantly increased from baseline at 16 out of the 18 time points in control HR, whereas the extracellular levels of dopamine did not differ from baseline at any time point in control LR (Fig. 5).

The effects of 15 mg/kg of COC on the extracellular amount of accumbal dopamine in novelty-challenged rats are depicted in Fig. 6a (LR COC: n = 8 and HR COC: n = 8). COC increased the extracellular dopamine levels in both HR [Fig. 6a; two-way ANOVA: treat × time effect: $F_{(18,270)} = 11.832, p < 0.001$] and LR [Fig. 6a; two-way ANOVA: treat × time effect: $F_{(18,252)} = 5.163, p < 0.001$]. However, the COC-induced increase of dopamine was stronger in HR than in LR [Fig. 6a; three-way ANOVA: type × treat × time effect: $F_{(18,522)} = 2.889, p < 0.001$]. Accumbal dopamine levels increased during the first 70 min in COC-treated HR (Fig. 6a; Student’s t-test), whereas accumbal dopamine levels increased only during the first 25 min in COC-treated LR (Fig. 6a; Student’s t-test). Pearson’s analysis revealed that both traveled distance and habituation time on the open-field positively correlated with the mean COC-induced increase of accumbal extracellular dopamine [Fig. 6b; LR and HR pooled (n = 16); distance (left): $R = 0.553, p = 0.02$; habituation time (right): $R = 0.572, p = 0.02$].

The effects of 1 mg/kg of RES on the COC-induced increase of extracellular accumbal dopamine are depicted in Fig. 7 (LR: RES 1 mg/kg + COC: n = 8 and HR: RES 1 mg/kg + COC: n = 8). The dose of 1 mg/kg of RES strongly reduced the COC-induced increase of extracellular dopamine in LR [Fig. 7a; two-way ANOVA: treat × time effect: $F_{(18,252)} = 5.263, p < 0.001$]. In fact, one sample t-test revealed that accumbal dopamine did not anymore increase from baseline at any time point in these rats (Fig. 7a). The dose of 1 mg/kg of RES did not at all affect the COC-
induced increase of extracellular dopamine levels in HR [Fig. 7b; two-way ANOVA: treat \times time effect: n.s; treat effect: n.s.]. One sample t-test revealed that accumbal dopamine significantly increased from baseline in HR during the first 65 min (Fig. 7b).

The effects of 2 mg/kg of RES on the extracellular amount of accumbal dopamine in COC-treated HR are also depicted in Fig. 7 (HR: RES 2 mg/kg + COC: n = 9). A two-way ANOVA revealed that the effects of RES were dose-dependent [Fig. 7b; dose \times time effect: F_{(36,396)} = 3.135, p < 0.001]. The dose of 2 mg/kg of RES strongly reduced the COC-induced increase of accumbal dopamine in HR [Fig. 7b; two-way ANOVA: treat \times time effect: F_{(18,270)} = 8.272, p < 0.001]. One sample t-test revealed that dopamine significantly increased from baseline only during the first 35 min [Fig. 7b].

Discussion

Accumbal levels of vesicular dopamine and VMAT-2 (experiments 1 + 2)

Low responders to novelty displayed smaller amounts of dopamine inside the storage vesicles of the nucleus accumbens than HR (see Fig. 2). These results can be explained by the finding that LR had less accumbal VMAT-2 than HR (see Fig. 3). It must be noted that two VMAT-2 proteins of different molecular size were identified. It has previously been shown that VMAT-2 proteins are expressed in two morphological distinct types of storage vesicles (Nirenberg et al. 1995, 1996, 1997). The small molecular size of VMAT-2 (\sim 70 kDa) has been found to be localized on small synaptic vesicles, whereas the large molecular size of VMAT-
2 (~110 kDa) has been found to be localized on large dense core vesicles, depending on the glycosylation of the protein (Yao et al. 2004; Yao and Hersh 2007). The present finding that LR displayed lower levels of both types of VMAT-2 than HR, indicates that LR are marked by smaller amounts of accumbal dopamine in both small and large vesicles than HR. These smaller levels of vesicular dopamine in LR than in HR may well account for the finding that the total levels of dopamine were smaller in LR than in HR (see Fig. 4).

**Fig. 4** Total levels of accumbal dopamine. The total amount of dopamine (pg) was determined in punches of accumbal tissue. Dopamine levels were quantified using tubulin for normalization (Fig. 3d). *Significant difference between LR (n = 10) and HR (n = 10) rats (one-way ANOVA). All data were expressed as mean ± SEM.

**Effects of reserpine on cocaine-induced accumbal dopamine levels (experiment 3)**

Cocaine increased the extracellular accumbal dopamine levels more strongly in HR than in LR (see Fig. 6a). These results in novelty-challenged rats are very similar to the previous reported results in non-novelty-challenged rats (Hooks et al. 1991b; Chefer et al. 2003). In fact, the dopamine increase after novelty hardly contributed to the dopamine increase after COC (see Fig. 6a). It was also demonstrated that both behavioral criteria to select HR and LR on the open-field (traveled distance and habituation time) positively correlated with the COC-induced increase of accumbal dopamine (see Fig. 6b). These data were in agreement with the previously reported notion that the response to novelty can predict the individual-specific response to drugs of abuse (Piazza et al. 1989, 1991a; Hooks et al. 1991a,b; Cools and Gingras 1998). The relatively low dose of 1 mg/kg of RES reduced the COC-induced increase of extracellular accumbal dopamine in LR, but not in HR (see Fig. 7). A higher dose of 2 mg/kg of RES was required to inhibit the COC-induced increase of accumbal dopamine in HR (see Fig. 7). These data confirm the hypothesis that COC-treated LR are more vulnerable to the RES-induced dopamine depletion than COC-treated HR.

Noradrenaline and serotonin are both known to control the release of dopamine (Kilpatrick et al. 1996; Cools and Tuinstra 2003). Because RES ultimately depletes dopamine, noradrenaline, and serotonin, the observed effects of RES may be the result of drug-induced changes in the levels of dopamine.

**Fig. 5** Effects of novelty (new cage) on the extracellular levels of dopamine in the nucleus accumbens in reserpine-solvent and saline-treated LR (circles) and reserpine-solvent and saline-treated HR (squares). Reserpine-solvent (1 mL/kg, i.p.) was administered 24 h before saline (1 mL/kg, i.p.). Rats (LR: n = 8 and HR: n = 9) were exposed to novelty immediately after the saline injection. Accumbal dopamine levels after novelty are expressed as percentage of baseline accumbal dopamine levels. The horizontal line represents basal dopamine levels (=100%). *Significant increase relative to baseline (one sample t-test). All data were expressed as mean ± SEM.

© 2008 The Authors
Journal Compilation © 2008 International Society for Neurochemistry, *J. Neurochem.* (2008) **105**, 2122–2133
Each of these neurotransmitters. However, the fact that the vesicular levels of dopamine differed between LR and HR, suggests that the observed individual differences in the effects of RES are, most likely, because of individual differences in the RES-induced decrease of the levels of dopamine inside storage vesicles.

One could argue that RES reduced the dopamine response to COC for the reason that RES diminished the basal levels of dopamine. Under the condition that COC blocks the re-uptake of neurotransmitters, low basal levels of extracellular dopamine result in a reduced COC-induced increase of dopamine. This explanation, however, is not supported by...
the present data. In HR, in which 1 mg/kg of RES strongly reduced the basal levels of dopamine (reduction 63%), the dopamine increase following COC was not inhibited at all (Fig. 7). Moreover, in LR, in which 1 mg/kg of RES only slightly reduced the basal levels of dopamine (reduction 15%), the dopamine increase following COC was completely inhibited (Fig. 7). The fact that the results in RES-treated rats cannot exclusively be explained by the generally accepted mode of action that COC inhibits dopamine re-uptake implies that COC must have an additional mode of action. The finding that RES reduced the extracellular dopamine increase to COC (Fig. 7) indicates that COC facilitates the release of dopamine that is derived from storage vesicles (Sulzer and Rayport 1990).

### Dopamine-releasing action of cocaine

The present data were in agreement with previously reported data demonstrating that the COC-induced release of dopamine is caused by exocytosis (Carboni et al. 1989; Yan 2003; Venton et al. 2006) and not by the reversal of plasmalemmal transporters (Fischer and Cho 1979; Butcher et al. 1988; Sulzer et al. 1993; Pifl et al. 1995; Scarpini et al. 1999). The exact mechanism of action for COC to release dopamine from vesicles is currently unknown. Superfusion studies have demonstrated that the dopamine and noradrenaline-releasing action of COC depends not only on storage pools, but also requires the inhibition of plasmalemmal transporters (Pifl et al. 1995, 1999). These data indicate that the COC-induced inhibition of dopamine transporters (DATs), somehow, promotes the dopamine release from vesicles. The notion that both DATs and dopaminergic storage vesicles are involved in the effects of COC in animals is confirmed by the outcome of studies in humans demonstrating that the chronic use of COC produces changes not only in DAT-binding, but also in VMAT-binding (Wilson et al. 1996; Little et al. 1999, 2003).

A dopamine-releasing action of COC involves that dopaminergic storage vesicles become empty after this drug (Pothos and Sulzer 1998; Pothos 2002). Under the condition that COC depletes dopaminergic storage vesicles, replenishment of these vesicles is required. In fact, it has recently been demonstrated that stimulation of D1 and D2 receptors promotes the refill of vesicles after dopamine has been released by transporter blockers like COC (Brown et al. 2001a,b; Sandoval et al. 2002). Given the observed individual differences in COC-induced dopamine release, this D1/D2-receptor mediated refill of vesicles is expected to be larger in COC-treated HR than in COC-treated LR. This nicely fits in with the finding that HR express more VMAT than LR.

### Effects of novelty on accumbal dopamine levels

The finding that HR that were exposed to saline and novelty were marked by a larger increase of extracellular accumbal dopamine than LR that were exposed to saline and novelty (see Fig. 5) fits in with the available literature reporting that challenged HR are marked by a larger accumbal dopamine response than challenged LR (Piazza et al. 1991b; Rouge-Pont et al. 1993; Saigusa et al. 1999; Verheij and Cools 2002).
2007). The finding, however, that the extracellular levels of dopamine did not at all increase in novelty-challenged LR is not in agreement with a previous study (Verheij and Cools 2007). It is important to note that the saline-treated and novelty-challenged rats of the present study were also treated with RES-solvent (see Experimental procedures). It has been shown that repeated exposure to the same stressor reduces, or even prevents, the stress-induced increase of dopamine in the nucleus accumbens (Imperato et al. 1992, 1993; Cabib and Puglisi-Allegra 1996a,b). Accordingly, the most likely explanation for the present finding that accumbal dopamine levels did not increase in novelty-challenged LR is that the rats of the present study were stressed twice by a systemic injection (RES solvent on day 1 and saline on day 2), whereas the rats of the previous study were stressed only once (RES solvent on day 1 and no saline on day 2). The previously reported finding that RES blocked the accumbal dopamine increase in novelty-challenged LR (Verheij and Cools 2007), suggest that the long-term processes that are triggered by multiple exposure to stressors (anticipation/adaptation) might be related to dopamine stored in RES-sensitive vesicles. The fact that RES did not at all inhibit the accumbal dopamine increase in novelty-challenged HR (Verheij and Cools 2007) may explain why the dopamine decreasing effects of repeated exposure to injection stress did not occur in these rats.

It has previously been reported that RES strongly reduces the baseline levels of dopamine in HR, but not LR (Verheij and Cools 2007). As discussed above, RES strongly reduces the dopamine response to novelty in LR, but not HR. The present study shows that RES decreased the dopamine response to COC in both types of rat. It is, therefore, suggested that the individual differences in (i) the basal dopamine response, (ii) the dopamine response to novelty, and (iii) the dopamine response to COC are regulated by three distinct neuronal substrates (for details see Verheij and Cools 2008).

Conclusion

The results of the present study indicate that the search for individual differences in the susceptibility to COC should focus not only on individual differences in the re-uptake mechanisms of dopamine, but also on individual differences in the capacity to store dopamine inside vesicles. The present data give rise to the conclusion that LR contain less dopamine inside accumbal storage vesicles than HR because the nucleus accumbens of LR display lower levels VMAT-2 than the nucleus accumbens of HR. The fact that LR are marked by a relatively small storage pool containing low amounts of VMAT, whereas HR are marked by a relatively large storage pool containing high amounts of VMAT may well explain why COC-treated LR are more vulnerable to the dopamine depleting effects of RES than COC-treated HR.

Although it is likely that several mechanisms contribute to individual differences in the sensitivity to COC, the results of the present study indicate that HR are more sensitive to COC than LR because COC can release more dopamine from accumbal storage vesicles in HR than in LR. Given that this release of vesicular dopamine may be mediated by dopamine re-uptake transporters, it is hypothesized that the individual differences in the COC-induced dopamine increase in HR and LR are due to a combination of individual differences in both dopamine re-uptake (Chefer et al. 2003) and vesicular dopamine release (present study).

Impact

The present findings open the intriguing possibility that drugs that deplete dopaminergic storage vesicles of the mesolimbic system (e.g. RES, Ro 4-1284, and tetrabenazine) might become the drugs of choice for the treatment of COC abuse. Interestingly, recent clinical screening trials on the effects of RES in COC-addicted subjects have already revealed promising results in this respect (Gorelick et al. 2004; Berger et al. 2005). RES-like agents have also been found to be effective in the treatment of hyperkinetic movements disorders like Huntington’s chorea (Huntington study group 2006; Kenney and Jankovic 2006). These results suggest that hyperkinesia may, at least in part, be mediated by dopamine derived from storage vesicles.

In addition to the effects of COC, the effects of methylphenidate (Ritalin) are also known to depend on RES-sensitive storage pools (Sheel-Kruger 1971; Chiueh and Moore 1975; Braestrup 1977; McMullen et al. 1980; McMillen 1983; Butcher et al. 1991). Methylphenidate is used to treat patients suffering from attention deficit hyperactivity disorder (ADHD). Studies in ADHD patients have revealed large individual differences in the clinical response to methylphenidate (Volkow et al. 2002; Volkow and Swanson 2003). Given that HR and LR differ in the size of the storage pools that are affected by these drugs, HR and LR may well be a used as an animal model to study the individual-specific variability in the treatment of ADHD (Wooters et al. 2006).

Finally, vesicular uptake is suggested to protect a neuron against the toxic effects of high levels of cytoplasmatic dopamine (Truong et al. 2003, 2004). In this respect, it is important to note that HR, which are marked by a large number of VMAT, are less sensitive to the neurotoxic effects of 6-hydroxydopamine than LR, which are marked by a small number of VMAT (van Oosten and Cools 2002).

Acknowledgements

This work was partly financed by a special incentive of the Ministry of Education and Science, The Netherlands, to promote top research at the Department of Psychoneuropharmacology (PNF).
Supplementary material

The following supplementary material is available for this article online:

Appendix S1 Full version of the section experimental procedures.

Fig S1 (A) Representative placement of 3 unilateral microdialysis probe tracks located in the right nucleus accumbens.

This material is available as part of the online article from http://www.blackwell-synergy.com.

Please note: Blackwell Publishing are not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

References

Abuthnott G. W., Fairbrother I. S. and Butcher S. P. (1990) Dopamine release and metabolism in the rat striatum: an analysis by ‘in vivo’ brain microdialysis. Pharmacol. Ther. 48, 281–293.

Ball S. A., Carroll K. M. and Rounsaville B. J. (1994) Sensation seeking, substance abuse, and psychopathology in treatment-seeking and community cocaine abusers. J. Consult. Clin. Psychol. 62, 1053–1057.

Berger S. P., Winhusen T. M., Somoza E. C. et al. (2005) A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 100(Suppl. 1), 58–67.

Bevins R. A., Klebar J. E. and Bardo M. T. (1997) Individual differences in response to novelty, amphetamine-induced activity and drug discrimination in rats. Behav. Pharmacol. 8, 113–123.

Braestrup C. (1977) Biochemical differentiation of amphetamine vs methylphenidate and nomifensine in rats. J. Pharmacol. Pharmacol. 29, 463–470.

van den Bree M. B., Johnson E. O., Neale M. C. and Pickens R. W. (1998) Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend. 52, 231–241.

Briegleb S. K., Gully J. M., Hoover B. R. and Zahnsier N. R. (2004) Individual differences in cocaine- and amphetamine-induced activation of male Sprague-Dawley rats: contribution of the dopamine transporter. Neuropsychopharmacology 29, 2168–2179.

Brown J. M., Hanson G. R. and Fleckenstein A. E. (2001a) Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J. Pharmacol. Exp. Ther. 298, 1150–1153.

Brown J. M., Hanson G. R. and Fleckenstein A. E. (2001b) Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 296, 762–767.

Butcher S. P., Fairbrother I. S., Kelly J. S. and Abuthnott G. W. (1998) Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem. 70, 346–355.

Butcher S. P., Liptrot J. and Abuthnott G. W. (1991) Characterisation of methylphenidate and nomifensine induced dopamine release in rat striatum using in vivo brain microdialysis. Neurosci. Lett. 122, 245–248.

Cabib S. and Puglisi-Allegra S. (1996a) Different effects of repeated stressful experiences on mesocortical and mesolimbic dopamine metabolism. Neuroscience 73, 375–380.

Cabib S. and Puglisi-Allegra S. (1996b) Stress, depression and the mesolimbic dopaminergic system. Psychopharmacology (Berl.) 128, 331–342.

Carboni E., Imperato A., Perezzani L. and Di Chiara G. (1989) Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28, 653–661.

Chefer V. I., Zakharova I. and Shippenberg T. S. (2003) Enhanced responsiveness to novelty and cocaine is associated with decreased basal dopamine uptake and release in the nucleus accumbens: quantitative microdialysis in rats under transient conditions. J. Neurosci. 23, 3076–3084.

Chiueh C. C. and Moore K. E. (1975) Blockade by reserpine of methyphenidate-induced release of brain dopamine. J. Pharmacol. Exp. Ther. 193, 559–563.

Chu D. T. and Klymkowsky M. W. (1989) The appearance of acetylated alpha-tubulin during early development and cellular differentiation in Xenopus. Dev. Biol. 136, 104–117.

Cools A. R. and Gingras M. A. (1998) Nijmegen high and low responders to novelty: a new tool in the search after the neurobiology of drug abuse liability. Pharmacol. Biochem. Behav. 60, 151–159.

Cools A. R. and Ttainstra T. (2003) Neurochemical evidence that mesolimbic noradrenaline directs mesolimbic dopamine, implying that noradrenaline, like dopamine, plays a key role in goal-directed and motivational behavior, in The Basal Ganglia VI: Advances in Behavioral Biology (Graybiel A. M., Delong M. R. and Kitai S. T., eds), Vol. 54, pp. 323–334. Plenum Publishers, New York.

Cools A. R., Brachten, R., Heeren D., Willemen A. and Ellenbroek B. (1990) Search after neurobiological profile of individual-specific features of Wistar rats. Brain Res. Bull. 24, 49–69.

Davis M. (1985) Cocaine: excitatory effects on sensorimotor reactivity measured with acoustic startle. Psychopharmacology (Berl.) 86, 31–36.

De Leonibus E., Verheij M. M., Mele A. and Cools A. (2006) Distinct kinds of novelty processing differentially increase extracellular dopamine in different brain regions. Eur. J. Neurosci. 23, 1332–1340.

Dellu F., Piazza P. V., Mayo W., Le Moal M. and Simon H. (1996) Novelty-seeking in rats—biobehavioral characteristics and possible relationship with the sensation-seeking trait in man. Neuropsychobiology 34, 136–145.

Fischer J. F. and Cho A. K. (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208, 203–209.

Fiorini S. M., Kuczenski R. and Segal D. S. (1995) Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J. Pharmacol. Exp. Ther. 274, 231–241.

Gorelick D. A., Gardner E. L. and Xi Z. X. (2004) Agents in development for the management of cocaine abuse. Drugs 64, 1547–1573.

Gynther L. M., Carey G., Gottesman I. I. and Vogler G. P. (1995) A twin study of non-alcohol substance abuse. Psychiatry Res. 56, 213–220.

Hedjam M., Leverin A. L., Eriksson K., Blomgren K., Mallard C. and Hagberg H. (2002) Interleukin-18 involvement in hypoxic-ischemic brain injury. J. Neurosci. 22, 5910–5919.

Henry J. P., Sagne C., Bedet C. and Gasnier B. (1998) The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem. Int. 32, 227–246.

Hooks M. S., Jones G. H., Smith A. D., Neill D. B. and Justice J.-B. J. (1999a) Individual differences in locomotor activity and sensitization. Pharmacol. Biochem. Behav. 68, 467–470.

Hooks M. S., Jones G. H., Smith A. D., Neill D. B. and Justice J.-B. J. (1999b) Response to novelty predicts the locomotor and nucleus accumbens dopamine response to cocaine. Synapse 9, 121–128.
Mong J. A., Devidze N., Frail D. E., O’Connor L. T., Samuel M., Huntington study group (2006) Tetrabenazine as antiichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66, 366–372.

Hurd Y. L. and Ungerstedt U. (1989) Cocaine: an in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse 3, 48–54.

Imperato A., Angelucci L., Casolini P., Zocchi A. and Puglisi-Allegra S. (1992) Repeated stressful experiences differently affect limbic dopamine release during and following stress. Brain Res. 577, 194–199.

Imperato A., Cabib S. and Puglisi-Allegra S. (1993) Repeated stressful experiences differently affect the time-dependent responses of the mesolimbic dopamine system to the stressor. Brain Res. 601, 333–336.

Jaffe L. T. and Archer R. P. (1987) The prediction of drug use among college students from MMPI, MCMI, and sensation seeking scales. J. Pers. Assess. 51, 243–253.

Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G. and Goedert M. (1998) Synapsin I/B phosphorylation in vitro by reserpine administered in vivo. J. Pharmacol. Exp. Ther. 141, 285–289.

Kabaj M. (2004) Neurobiological bases of individual differences in emotional and stress responsiveness: high responders-low responders model. Arch. Neurol. 61, 1009–1012.

Kenney C. and Jankovic J. (2006) Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev. Neurother. 6, 7–17.

Kilpatrick G. J., Hagan R. M. and Gale J. D. (1996) 5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system. Behav. Brain Res. 73, 11–13.

Kirsner N., Rorie M. and Kamin D. L. (1963) Inhibition of dopamine uptake in vitro by reseprime administered in vivo. J. Pharmacol. Exp. Ther. 141, 285–289.

Kong L. W., Ding X. Y., Kitani H., Shiurba R. and Jing N. H. (1999) Evidence for a mouse brain-specific variant of alpha-tubulin. Cell Res. 9, 315–325.

Lee T. H., Bala R., Davidson C. and Ellinwood E. H. (2001) Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors. Synapse 41, 301–310.

Leviel V., Gobert A. and Guibert B. (1989) Direct observation of dopamine compartmentation in striatal nerve terminal by ‘in vivo’ measurement of the specific activity of released dopamine. Brain Res. 499, 205–213.

Little K. Y., Zhang L., Desmond T., Frey K. A., Dalack G. W. and Cassin B. J. (1999) Striatal dopaminergic abnormalities in human cocaine Users. Am. J. Psychiatry 156, 238–245.

Little K. Y., Krolowski D. M., Zhang L. and Cassin B. J. (2003) Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am. J. Psychiatry 160, 47–55.

Mantsch J. R., Ho A., Schlussman S. D. and Kreek M. J. (2001) Predictable individual differences in the initiation of cocaine self-administration by rats under extended-access conditions are dose-dependent. Psychopharmacology (Berl.) 157, 31–39.

McMenen B. A. (1983) CNS stimulants: two distinct mechanisms of action for amphetamine-like drugs. Trends Pharmacol. Sci. 4, 429–432.

McMenen B. A., German D. C. and Shore P. A. (1980) Functional and pharmacological significance of brain dopamine and norepinephrine storage pools. Biochem. Pharmacol. 29, 3045–3050.

Mong J. A., Devizde N., Frail D. E., O’Connor L. T., Samuel M., Choleris E., Ogawa S. and Pfaff D. W. (2003) Estradiol differentially regulates lipocalin-type prostaglandin D synthase transcript levels in the rodent brain. Evidence from high-density oligonucleotide arrays and in situ hybridization. Proc. Natl Acad. Sci. USA 100, 318–323.

Nirenberg M. J., Liu Y., Peter D., Edwards R. H. and Pickel V. M. (1995) The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. Proc. Natl Acad. Sci. USA 92, 8773–8777.

Nirenberg M. J., Chan J., Liu Y., Edwards R. H. and Pickel V. M. (1996) Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J. Neurosci. 16, 4135–4145.

Nirenberg M. J., Chan J., Liu Y., Edwards R. H. and Pickel V. M. (1997) Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals. Synapse 26, 194–198.

Oosten R. V. and Cools A. R. (2002) Differential effects of a small, unilateral, 6-hydroxydopamine-induced nigral lesion on behavior in high and low responders to novelty. Exp. Neurol. 173, 245–255.

Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Elsevier Academic Press, San Diego.

Piazza P. V., Deminiere J. M., Le Moal M. and Simon H. (1989) Factors that predict individual vulnerability to amphetamine self-administration. Science 245, 1511–1513.

Piazza P. V., Macsari S., Deminiere J. M., Le Moal M., Mormede P. and Simon H. (1991a) Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc. Natl Acad. Sci. USA 88, 2088–2092.

Piazza P. V., Rouge-Pont F., Deminiere J. M., Khoubi M., Le Moal M. and Simon H. (1991b) Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. Brain Res. 567, 169–174.

Piazza P. V., Deroche-Gamonvet V., Rouge-Pont F. and Le Moal M. (2000) Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction. J. Neurosci. 20, 4226–4232.

Pill C., Droby H., Reither H., Hornykiewicz O. and Singer E. A. (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmaemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47, 368–373.

Pill C., Agneter E., Droby H., Sitte H. H. and Singer E. A. (1999) Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology 38, 157–165.

Potthos E. N. (2002) Regulation of dopamine quantal size in midbrain and hippocampal neurons. Behav. Brain Res. 130, 203–207.

Potthos E. N. and Sulzer D. (1998) Modulation of quantal dopamine release by psychostimulants. Adv. Pharmacol. 42, 198–202.

Potthos E. N., Larsen K. E., Krantz D. E., Liu Y., Haycock J. W., Setlik W., Gershon M. D., Edwards R. H. and Sulzer D. (2000) Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 20, 7297–7306.

Rouge-Pont F., Piazza P. V., Khoubi M., Le Moal M. and Simon H. (1993) Higher and longer stress-induced increase in dopamine concentrations in the nucleus accumbens of animals predisposed to amphetamine self-administration. A microdialysis study. Brain Res. 602, 169–174.

Sabetti J., Gerhardt G. A. and Zahniser N. R. (2002) Acute cocaine differentially alters accumbens and striatal dopamine clearance in low and high cocaine locomotor responders: behavioral and electrochemical recordings in freely moving rats. J. Pharmacol. Exp. Ther. 302, 1201–1211.

Sabetti J., Gerhardt G. A. and Zahniser N. R. (2003) Individual differences in cocaine-induced locomotor sensitization in low and high cocaine locomotor-responding rats are associated with differential inhibition of dopamine clearance in nucleus accumbens. J. Pharmacol. Exp. Ther. 305, 180–190.
Saigusa T., Tuinstra T., Koshikawa N. and Cools A. R. (1999) High and low responders to novelty: effects of a catecholamine synthesis inhibitor on novelty-induced changes in behaviour and release of accumbal dopamine. *Neuroscience* **88**, 1153–1163.

Sandoval V., Riddle E. L., Hanson G. R. and Fleckenstein A. E. (2002) Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. *J. Neurosci.* **22**, 8705–8710.

Sandoval V., Riddle E. L., Hanson G. R. and Fleckenstein A. E. (2003) Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. *J. Pharmacol. Exp. Ther.* **304**, 1181–1187.

Scarponi M., Bernardi G. and Mercuri N. B. (1999) Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons. *Eur. J. Neurosci.* **11**, 593–598.

Scheel-Kruger J. (1971) Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain. *Eur. J. Pharmacol.* **14**, 47–59.

Scheel-Kruger J., Braestrup C., Nielson M., Golembiowska K. and Mogilnicka E. (1977) Cocaine: discussion on the role of dopamine in the biochemical mechanism of action, in *Advances in Behavioral Biology* (Ellinwood E. H. Jr and Kilbey M. M., eds.), pp. 373–407. Plenum press, New York.

Schoemaker H. and Nickolson V. J. (1983) Dopamine uptake by rat striatal synaptosomes: a compartmental analysis. *J. Neurochem.* **41**, 684–690.

Staal R. G., Hogan K. A., Liang C. L., German D. C. and Sonsalla P. K. (2000) In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. *J. Pharmacol. Exp. Ther.* **293**, 329–335.

Sulzer D. and Rayport S. (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. *Neuron* **5**, 797–808.

Sulzer D., Maidment N. T. and Rayport S. (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. *J. Neurochem.* **60**, 527–535.

Szczypka M. S., Kwok K., Brot M. D., Marek B. T., Matsumoto A. M., Donahue B. A. and Palmiter R. D. (2001) Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. *Neuron* **30**, 819–828.

Truong J. G., Rau K. S., Hanson G. R. and Fleckenstein A. E. (2003) Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson’s neurodegeneration. *Eur. J. Pharmacol.* **474**, 223–226.

Truong J. G., Hanson G. R. and Fleckenstein A. E. (2004) Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration. *Eur. J. Pharmacol.* **492**, 143–147.

Venton B. J., Seipel A. T., Phillips P. E., Wetsel W. C., Gitler D., Greengard P., Augustine G. J. and Wightman R. M. (2006) Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. *J. Neurosci.* **26**, 3206–3209.

Verheij M. M. and Cools A. R. (2007) Differential contribution of storage pools to the extracellular amount of accumbal dopamine in high and low responders to novelty: effects of reserpine. *J. Neurochem.* **100**, 810–821.

Verheij M. M. and Cools A. R. (2008) Twenty years of dopamine research: individual differences in the response of accumbal dopamine to environmental and pharmacological challenges. *Eur. J. Pharmacol.* In press.

Volkow N. D. and Swanson J. M. (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. *Am. J. Psychiatry* **160**, 1909–1918.

Volkow N. D., Wang G. J., Fowler J. S. et al. (2002) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. *Synapse* **43**, 181–187.

Wilson J. M., Levey A. I., Bergeron C. et al. (1996) Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. *Ann. Neurol.* **40**, 428–439.

Wooters T. E., Dwoskin L. P. and Bardo M. T. (2006) Age and sex differences in the locomotor effect of repeated methylphenidate in rats classified as high or low novelty responders. *Psychopharmacology (Berl.)* **188**, 18–27.

Yan Q. S. (2003) Involvement of non-exocytotic mechanisms in ethanol-induced in vivo dopamine release: comparisons with cocaine. *Eur. J. Pharmacol.* **477**, 37–44.

Yao J. and Hersh L. B. (2007) The vesicular monoamine transporter 2 contains trafficking signals in both its N-glycosylation and C-terminal domains. *J. Neurochem.* **100**, 1387–1396.

Yao J., Erickson J. D. and Hersh L. B. (2004) Protein kinase A affects trafficking of the vesicular monoamine transporters in PC12 cells. *Traffic* **5**, 1006–1016.

Zahniser N. R. and Sorkin A. (2004) Rapid regulation of the dopamine transporter: role in stimulant addiction? *Neuropharmacology* **47**(Suppl. 1), 80–91.